Part of the book: Hypercholesterolemia
Statins are the most used therapeutic group in the treatment of hypercholesterolemia and reduce the risk of cardiovascular events and mortality. Long prescription periods and their pharmacokinetic characteristics increase the possibility of interactions, especially at the metabolism level. Simvastatin, lovastatin, and atorvastatin are metabolized by CYP3A4 isoenzymes, so they will have more significant interactions than fluvastatin, pitavastatin, and rosuvastatin that require CYP2C9. The main interactions are with macrolides, azole antifungals, antiretrovirals, platelet antiaggregants, anticoagulants, oral antidiabetics, calcium channel blockers, immunosuppressants, and other hypolipidemic agents, among others. A review of all medications that are taken by patients treated with statins should be performed at each medical consultation and during all healthcare transitions.
Part of the book: Cardiovascular Risk Factors in Pathology
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pro-inflammatory and prothrombogenic virus with a high mutagenic profile, which produces active infection of variable duration in various organs and systems, and it has been observed that patients who have already suffered from the disease, especially in its more severe forms such as bilateral pneumonia or respiratory distress, present symptoms and signs of chronic multi-organ involvement. However, little is known about the molecular mechanisms that generate endothelial damage (chronic reactive endotheliitis) and subsequent thrombosis in SARS-CoV-2 infection are still not sufficiently elucidated, and in this chapter, we explore these mechanisms and therapeutic options to reduce prothrombosis and multiple vascular involvement that cause morbidity and mortality in this disease. In particular, we will evaluate heparin doses according to the stage of infection and its correlation with improved survival.
Part of the book: Anticoagulation